Puma Biotechnology, Inc.
PBYI
$6.07
$0.172.88%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 228.37M | 212.00M | 238.06M | 232.71M | 230.47M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 228.37M | 212.00M | 238.06M | 232.71M | 230.47M |
| Cost of Revenue | 58.16M | 48.95M | 65.88M | 64.23M | 64.40M |
| Gross Profit | 170.21M | 163.04M | 172.19M | 168.48M | 166.06M |
| SG&A Expenses | 70.85M | 69.09M | 69.09M | 76.02M | 80.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 191.07M | 178.44M | 192.00M | 195.46M | 199.50M |
| Operating Income | 37.30M | 33.56M | 46.06M | 37.25M | 30.97M |
| Income Before Tax | 35.78M | 30.91M | 42.28M | 31.96M | 24.10M |
| Income Tax Expenses | 4.67M | -6.07M | -6.17M | -6.11M | -6.18M |
| Earnings from Continuing Operations | 31.11 | 36.98 | 48.45 | 38.07 | 30.28 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.11M | 36.98M | 48.45M | 38.07M | 30.28M |
| EBIT | 37.30M | 33.56M | 46.06M | 37.25M | 30.97M |
| EBITDA | 47.44M | 43.28M | 55.94M | 47.27M | 41.09M |
| EPS Basic | 0.62 | 0.75 | 0.99 | 0.77 | 0.61 |
| Normalized Basic EPS | 0.45 | 0.39 | 0.54 | 0.41 | 0.31 |
| EPS Diluted | 0.61 | 0.74 | 0.98 | 0.77 | 0.61 |
| Normalized Diluted EPS | 0.44 | 0.39 | 0.53 | 0.40 | 0.30 |
| Average Basic Shares Outstanding | 199.97M | 198.73M | 197.40M | 195.99M | 194.59M |
| Average Diluted Shares Outstanding | 202.50M | 200.39M | 198.63M | 196.78M | 195.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |